MX2022009753A - Composiciones y metodos para el tratamiento de la enfermedad de pompe. - Google Patents
Composiciones y metodos para el tratamiento de la enfermedad de pompe.Info
- Publication number
- MX2022009753A MX2022009753A MX2022009753A MX2022009753A MX2022009753A MX 2022009753 A MX2022009753 A MX 2022009753A MX 2022009753 A MX2022009753 A MX 2022009753A MX 2022009753 A MX2022009753 A MX 2022009753A MX 2022009753 A MX2022009753 A MX 2022009753A
- Authority
- MX
- Mexico
- Prior art keywords
- pompe disease
- compositions
- methods
- treating pompe
- oligosaccharide
- Prior art date
Links
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 title abstract 2
- 206010053185 Glycogen storage disease type II Diseases 0.000 title abstract 2
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 title abstract 2
- 201000004502 glycogen storage disease II Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000036545 infantile onset glycogen storage disease due to acid maltase deficiency Diseases 0.000 abstract 2
- 102000004366 Glucosidases Human genes 0.000 abstract 1
- 108010056771 Glucosidases Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229950009574 avalglucosidase alfa Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062971930P | 2020-02-08 | 2020-02-08 | |
| US202063115975P | 2020-11-19 | 2020-11-19 | |
| PCT/US2021/017113 WO2021159092A1 (en) | 2020-02-08 | 2021-02-08 | Compositions and methods for treating pompe disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009753A true MX2022009753A (es) | 2022-09-07 |
Family
ID=74853758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009753A MX2022009753A (es) | 2020-02-08 | 2021-02-08 | Composiciones y metodos para el tratamiento de la enfermedad de pompe. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12251430B2 (https=) |
| EP (1) | EP4100120A1 (https=) |
| JP (2) | JP7804582B2 (https=) |
| KR (1) | KR20220139936A (https=) |
| CN (1) | CN115715218A (https=) |
| AU (1) | AU2021216055A1 (https=) |
| BR (1) | BR112022015505A2 (https=) |
| CA (1) | CA3167091A1 (https=) |
| IL (1) | IL295415A (https=) |
| MX (1) | MX2022009753A (https=) |
| WO (1) | WO2021159092A1 (https=) |
| ZA (1) | ZA202209925B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021216055A1 (en) | 2020-02-08 | 2022-09-29 | Genzyme Corporation | Compositions and methods for treating pompe disease |
| MX2022016019A (es) | 2020-06-14 | 2023-04-10 | Genzyme Corp | Composiciones y metodos para el tratamiento de enfermedad de pompe de inicio tardio. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| EP1877099B1 (en) | 2005-04-06 | 2012-09-19 | Genzyme Corporation | Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety |
| SI2457920T1 (en) | 2007-01-18 | 2018-02-28 | Genzyme Corporation | Oligosaccharides containing the amino acid group and their conjugates |
| CA3040973A1 (en) * | 2008-12-16 | 2010-07-01 | Genzyme Corporation | Oligosaccharide-protein conjugates |
| CN110124039A (zh) | 2011-05-16 | 2019-08-16 | 建新公司 | 使用甲氨蝶呤诱导免疫耐受性 |
| US10172924B2 (en) * | 2015-03-19 | 2019-01-08 | Translate Bio, Inc. | MRNA therapy for pompe disease |
| KR102510941B1 (ko) * | 2015-12-30 | 2023-03-20 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병 치료용의 강화된 산 알파-글루코시다제 |
| AU2021216055A1 (en) | 2020-02-08 | 2022-09-29 | Genzyme Corporation | Compositions and methods for treating pompe disease |
-
2021
- 2021-02-08 AU AU2021216055A patent/AU2021216055A1/en active Pending
- 2021-02-08 CA CA3167091A patent/CA3167091A1/en active Pending
- 2021-02-08 JP JP2022547874A patent/JP7804582B2/ja active Active
- 2021-02-08 KR KR1020227030889A patent/KR20220139936A/ko active Pending
- 2021-02-08 CN CN202180013438.1A patent/CN115715218A/zh active Pending
- 2021-02-08 BR BR112022015505A patent/BR112022015505A2/pt unknown
- 2021-02-08 MX MX2022009753A patent/MX2022009753A/es unknown
- 2021-02-08 WO PCT/US2021/017113 patent/WO2021159092A1/en not_active Ceased
- 2021-02-08 IL IL295415A patent/IL295415A/en unknown
- 2021-02-08 US US17/170,667 patent/US12251430B2/en active Active
- 2021-02-08 EP EP21709562.9A patent/EP4100120A1/en active Pending
-
2022
- 2022-09-06 ZA ZA2022/09925A patent/ZA202209925B/en unknown
-
2025
- 2025-02-13 US US19/053,240 patent/US20250319166A1/en active Pending
- 2025-08-22 JP JP2025138630A patent/JP2025166240A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021216055A1 (en) | 2022-09-29 |
| CN115715218A (zh) | 2023-02-24 |
| TW202142264A (zh) | 2021-11-16 |
| JP2025166240A (ja) | 2025-11-05 |
| KR20220139936A (ko) | 2022-10-17 |
| EP4100120A1 (en) | 2022-12-14 |
| BR112022015505A2 (pt) | 2022-09-27 |
| CA3167091A1 (en) | 2021-08-12 |
| JP2023512783A (ja) | 2023-03-29 |
| JP7804582B2 (ja) | 2026-01-22 |
| WO2021159092A1 (en) | 2021-08-12 |
| US20250319166A1 (en) | 2025-10-16 |
| ZA202209925B (en) | 2026-01-28 |
| US12251430B2 (en) | 2025-03-18 |
| US20210244803A1 (en) | 2021-08-12 |
| IL295415A (en) | 2022-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023008895A (es) | Conjugado de sustancia bioactiva, metodo de preparacion y uso del mismo. | |
| CO2022008969A2 (es) | Tetrahidrofuranos sustituidos como moduladores de canales de sodio | |
| MX2022010515A (es) | Conjugacion mediada por transglutaminasa. | |
| ECSP088412A (es) | Derivados de pirazina como moduladores de canal de sodio en el tratamiento del dolor | |
| BR112022002720A2 (pt) | Formulações de conjugados de benzazepinas e usos das mesmas | |
| ECSP22056585A (es) | Variantes de alfa-glucosidasa ácida diseñadas por ingeniería | |
| CO2023006684A2 (es) | Anticuerpos contra sars-cov-2 y usos de los mismos | |
| BR112021025720A2 (pt) | Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados | |
| DOP2024000209A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| CL2022000319A1 (es) | Derivados de amidas híbridas de anfotericina b | |
| CL2009001215A1 (es) | Composiciones farmaceuticas que comprenden un primer agente seleccionado del grupo consistente de i) un agente antiinflamatorio, ii) acetaminofeno, iii) fenacetina, iv) tramadol, y un segundo agente; uso de dichas composiciones para tratar enfermedades proliferativas incluyendo cancer. | |
| MX2023012848A (es) | Conjugados de anticuerpo-farmaco anti-c-met. | |
| CL2021002838A1 (es) | Anticuerpo anti-bcma conjugado, composiciones que comprenden el mismo, y métodos de fabricación y uso del mismo. | |
| CO2024015816A2 (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| MX2022009753A (es) | Composiciones y metodos para el tratamiento de la enfermedad de pompe. | |
| CO2023005889A2 (es) | Formulación de conjugado anticuerpo-fármaco de ceacam5 | |
| CO2025001970A2 (es) | Composiciones dirigidas a la proteína de activación de fibroblastos y métodos para el uso de las mismas | |
| BR112023019698A2 (pt) | Construtos de anticorpo modificados por cisteína, conjugados e métodos de uso | |
| UY40795A (es) | Péptidos dirigidos a dll3 y constructos de los mismos | |
| CL2025002746A1 (es) | Trans-cicloocteno con enlazador-t mejorado | |
| UY40792A (es) | Péptidos dirigidos a dll3 y constructos de los mismos | |
| MX2024003093A (es) | Administracion facilitada de formulaciones concentradas de anticuerpos mediante el uso de hialuronidasa. | |
| AR132362A1 (es) | Conjugados que comprenden enlazadores escindibles | |
| CL2024002379A1 (es) | Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso | |
| CR20240489A (es) | Agentes aglutinantes 5t4 y usos de los mismos |